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Suppression of BCL6 function 
by HDAC inhibitor mediated 
acetylation and chromatin 
modification enhances BET 
inhibitor effects in B-cell lymphoma 
cells
María G. cortiguera1,2,4, Lorena García-Gaipo1,4, Simon D. Wagner3, Javier León1,  
Ana Batlle-López2* & M. Dolores Delgado1*
Multiple genetic aberrations in the regulation of BCL6, including in acetyltransferase genes, occur 
in clinically aggressive B-cell lymphomas and lead to higher expression levels and activity of this 
transcriptional repressor. BCL6 is, therefore, an attractive target for therapy in aggressive lymphomas. 
In this study romidepsin, a potent histone deacetylase inhibitor (HDACi), induced apoptosis and cell 
cycle arrest in Burkitt and diffuse large B-cell lymphoma cell lines, which are model cells for studying 
the mechanism of action of BCL6. Romidepsin caused BCL6 acetylation at early timepoints inhibiting its 
function, while at later timepoints BCL6 expression was reduced and target gene expression increased 
due to chromatin modification. MYC contributes to poor prognosis in aggressive lymphoma. MYC 
function is reduced by inhibition of chromatin readers of the bromodomain and extra-terminal repeat 
(BET) family, which includes BRD4. The novel combination of romidepsin and JQ1, a BRD4 inhibitor was 
investigated and showed synergy. Collectively we suggest that the combination of HDACi and BRD4i 
should be pursued in further pre-clinical testing.
Aggressive lymphomas such as diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL) are a heter-
ogeneous group of disorders in terms of clinical behavior, biological characteristics and response to treatments1. 
Despite improvements in diagnosis and treatment, non-Hodgkins-lymphomas are still an important cause of 
morbidity and mortality worldwide. Combination of rituximab with anthracycline-based chemotherapy regimen, 
such as R-CHOP (Rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone) is effective2 but over-
all >40% of patients are not cured of their disease. Thus, it is important to identify new approaches to therapy. 
Aggressive lymphomas are often derived from germinal center B-cells. Germinal centers are dynamic structures 
within normal lymph nodes, where B-cells proliferate intensely and undergo somatic hypermutation3, a process 
involving the production of DNA breaks that is essential for the formation of high affinity antibodies. Conditions 
within the germinal center are therefore believed to predispose to the formation of lymphomas3. There is a wealth 
of genetic evidence that BCL6 contributes to the survival of DLBCL and clinical evidence suggests that a propor-
tion of BCL6 expressing DLBCL patients have poor clinical outcomes. The role of BCL6 in Burkitt lymphoma 
has not been investigated but it is expressed in all cases and is likely to contribute to proliferation and survival.
BCL6 is a master transcription factor that is essential for normal germinal center formation4,5. Enforced 
expression of BCL6 in mice is sufficient for the development of lymphomas6. Multiple genetic abnormalities 
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leading to increased BCL6 expression have been described7,8 and BCL6 is also involved in chromosomal trans-
locations in ~25% of DLBCL9. Thus, modulation of BCL6 expression could be a potential target for therapy in 
lymphomas. Indeed, BCL6 inhibition using specific inhibitors was able to produce apoptosis and cell cycle arrest 
of these cells10,11 suggesting that BCL6 may be a promising therapeutic target in lymphoma12,13.
We and others, have recently shown that epigenetic mechanisms are involved in BCL6 regulation14–16. Histone 
deacetylase inhibitors (HDACi) are a novel class of antitumor agents that have shown very promising results for 
the treatment of a number of hematologic malignancies17,18. Regulation of the reversible acetylation status of an 
increasing number of non-histone proteins, many of them being proto-oncogenes, allows to modulate a number 
of essential cellular processes such as protein interactions, protein stability, apoptosis, cell proliferation and cell 
survival19. Particularly, HDAC inhibitors have been shown to inhibit BCL6 function by inducing its acetylation, 
which leads to de-repression of its target genes20. Romidepsin is an HDACi with high inhibitory activity for class 
I histone deacetylases that is approved by the FDA for the treatment of cutaneous T-cell lymphoma or refractory/
relapsed peripheral T-cell lymphoma21,22. HDACi synergize with other agents including hypomethylating agents 
in pre-clinical models of DLBCL23.
MYC translocations occur in 10–15% of DLBCL1. High expression of MYC, independent of the pres-
ence of chromosomal translocations involving MYC, is associated with poor clinical outcome in B-cell lym-
phoma24,25. There is interest in the bromodomain and extra-terminal (BET) family member BRD4, which 
recognizes acetylated histones and plays an essential role in the regulation of MYC expression26. BRD4 
(bromodomain-containing protein-4) inhibitors27 such as JQ1 are able to cause MYC oncogene downregulation 
in a variety of human cancers, including leukemia and lymphoma28. BET inhibitors are currently being used in 
clinical trials29.
Promising data on combining HDACi with BRD4 inhibitors has been reported18. This combination has a 
specific rationale in DLBCL and BL as it potentially targets MYC in poor prognosis disease. Thus, the aim of this 
study was to investigate the effects of romidepsin alone or in combination with the BRD4 inhibitor, JQ1, in the 
treatment of aggressive lymphomas, and to identify the molecular mechanisms involved in its effects.
Results
Romidepsin promotes apoptosis in cells from agressive lymphomas. As a first approach, we meas-
ured cell proliferation (based on metabolic activity) upon romidepsin treatment to establish a dose-response 
assessment and to analyze the effect of the HDACi on proliferation at different time points (Fig. 1a). Romidepsin 
was tested in different types of aggressive B-cell lymphoma cell lines: three Burkitt lymphoma cell lines (Raji, 
DG75 and Ramos), one GC-DLBCL (Toledo) and one ABC-DLBCL (Ly03) (see Supplementary Table S1).
At 48 h, Raji and DG75 cells showed little (10–20%) reduction of metabolic activity (Fig. 1a), even with the 
highest doses tested (10 nM). Ramos cells were the most sensitive, showing a metabolic reduction 50% after treat-
ment with romidepsin (5 nM) while both Toledo and Ly03, showed intermediate sensitivity. Very high doses of 
romidepsin inhibit almost completely the proliferation of all the lymphoma cell lines studied (not shown). Given 
that with 1 nM concentration did not show any significant effect on the studied cell lines and 10 nM treatment 
resulted in cell death for the most sensitive cell lines, we chose 2 nM and 5 nM as optimal concentrations for fur-
ther experiments.
To evaluate the effects of romidepsin on apoptosis, Annexin V binding was determined (Fig. 1b). No signifi-
cant cell death was observed for the metabolically less-sensitive cell lines Raji and DG75, while the sensitive cell 
lines Ramos, Toledo and Ly03, showed significant apoptosis induction after treatment with romidepsin (5 nM) 
(Fig. 1b). The apoptotic effects of this drug were verified using the PARP1 cleavage assay. Cleaved PARP1 was 
found in the high and moderate sensitive cell lines (Ramos, Toledo and Ly03) but not in the less sensitive ones 
(Raji and DG75) (Fig. 1c).
We next examined the effect of romidepsin on expression of some BCL2 family members (Fig. 2). The intrin-
sic apoptotic pathway can be primarily activated by chemotherapeutic drugs and various studies support its role 
in HDACi mediated cell death30. In agreement with previous reports, BCL2 expression was neither observed in 
Ramos or DG75 in basal conditions31,32 or upon treatment with romidepsin. There was little change in the level of 
BCL2 in Raji and Toledo while there was suppression in Ly03 (Fig. 2a), confirming previous results indicating that 
romidepsin is able to induce apoptosis despite BCL2 expression33. Other pro-survival proteins were investigated: 
BCL-xL levels were high in basal conditions and were reduced upon treatment in the sensitive cell lines with the 
exception of Ly03 (Fig. 2b), suggesting that downregulation of BCL-xL might be mediating romidepsin apoptotic 
effect on germinal center derived cells. Transient expression or little change was observed in MCL1 levels with 
romidepsin (Fig. 2c). Interestingly, the pro-apoptotic protein BIM (Fig. 2d), showed some increase with romidep-
sin in DLBCL cell lines (Toledo and Ly03), which was in agreement with the PARP1 cleavage pattern detected 
with romidepsin treatment.
Altogether, these results demonstrate that romidepsin can repress metabolic activity and induce variable lev-
els of apoptosis associated with changes in expression of BCL2 family proteins that might be different upon the 
different subtypes of lymphomas.
Romidepsin induces cell cycle arrest accompanied with p21 and p27 up-regulation. Romidepsin 
has previously been shown to induce cell cycle arrest in cells from different tissues22. Based on this information, 
we aimed to analyze the cell cycle in cell lines with different responses to the HDACi (Fig. 3a). The fraction of 
cells in the sub-G0/G1 phase upon 48 h of romidepsin treatment, corresponding to subdiploid dead cells (inset 
in Fig. 3a), is in agreement with the apoptosis observed in the sensitive Ramos, Toledo and Ly03 cells (Fig. 1). 
In Raji and DG75, the percentage of cells in sub-G0/G1 did not change upon romidepsin (inset in Fig. 3a), how-
ever a significant accumulation of cells in G0/G1 was found (main graph in Fig. 3a) indicating that even in those 
less-sensitive cells, a certain antiproliferative effect was observed. For Ramos and Ly03 the accumulation in G0/G1 
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Figure 1. Romidepsin effect on B-cell lymphoma cells proliferation and apoptosis. (a) The indicated cell lines 
were treated with different concentrations of romidepsin and metabolic activity was determined using WST-1 
method at the designated times. Untreated cells represented 100% of metabolic activity. The data show the 
means ± s.e.m. of four measurements in two independent experiments. (b) Annexin V staining to assess early 
apoptosis in B-cell lymphoma cells untreated (control) or cells treated with 5 nM romidepsin for 48 h. One 
representative experiment is shown for each cell line. The graphs on the right represent percentages of Annexin 
V positive cells. The data show the means ± s.e.m. of two or three independent experiments; significance 
difference (*p < 0.05) from the control untreated cells. (c) Western blot showing PARP1 and cleaved-PARP1 
(indicated with an asterisk) in B-cell lymphoma cells treated with romidepsin at the indicated times and 
concentrations. Actin was used as loading control. The blots were cropped for improved clarity and the full-
length blots were included in the Supplementary Information file.
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was smaller but still statistically significant. The cell population distribution in Toledo cell line was not substan-
tially affected (main graph in Fig. 3a).
Given the effects of HDACi on cell cycle arrest, we wonder whether the cell cycle inhibitors p27Kip1 (p27) and 
p21Cip1 (p21) were involved as has been reported for other HDACi34. We observed an increase of p21 protein 
levels in DG75 and Ramos cells treated with romidepsin (Fig. 3b). The increase in p21 in Toledo cells was no so 
prominent, probably reflecting the lack of cell cycle arrest in these cells. Additionally, levels of p27 were increased 
in Raji, DG75, Ramos and Ly03 in the presence of romidepsin (Fig. 3b). There is, therefore, no clear agreement 
between protein levels of p21 and p27 and the clear block in G1 phase that the drug provokes across all these cell 
lines (Fig. 3a). Overall, romidepsin induces cell cycle arrest together with increase in p21 and p27 expression in 
Ramos, the most sensitive cell line.
Romidepsin provokes BCL6 downregulation and triggers plasma cell differentiation. BCL6 is a 
transcriptional repressor and one of the “master regulators” that controls the exit of the B-cells from the germinal 
centers in order to differentiate toward plasma cells3. To determine the effect of romidepsin on BCL6 expression, 
we analyze the effect of this histone deacetylase inhibitor on several BL cell lines with different BCL6 expression 
levels (see Supplementary Table S1). Romidepsin reduced BCL6 mRNA (not shown) and protein levels (Fig. 4a) 
in a dose and time dependent manner. In DG75, BCL6 downregulation takes place after 24 hours of romidepsin 
treatment either with 2 nM or 5 nM concentrations. In Raji and Ramos, reduced BCL6 levels were observed upon 
48 to 72 hours of treatment. Romidepsin effects on CCND2 (Cyclin D2), a direct target of BCL635, were evalu-
ated. We found a strong increase in the CCND2 mRNA levels in Raji and DG75 in response to romidepsin, and 
a modest upregulation in Ramos cells (Fig. 4b), supporting a functionally important downregulation of BCL6 by 
romidepsin.
BCL6 downregulation is essential for B-cells to leave the germinal center and to differentiate towards plasma 
cell. As a consequence of BCL6 downregulation, induction of target genes essential for B-cells to differentiate into 
plasma cells, such as PRDM1 (BLIMP1), takes place. We analyzed PRDM1 mRNA levels in the B-cell lymphoma 
Figure 2. BCL2 family protein expression upon romidepsin treatment. Western blot showing BCL2 (a), 
BCL-xL (b), MCL1 (c) and BIM (d) protein expression in B-cell lymphoma cells treated with 2 or 5 nM 
romidepsin for the indicated times. Actin or GAPDH were used as loading controls. Densitometry values are 
shown at the bottom, normalized to the control. The blots were cropped for improved clarity and the full-length 
blots were included in the Supplementary Information file.
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Figure 3. Cell cycle distribution and cell cycle inhibitors expression in B-cell lymphoma cells in the presence 
of romidepsin. (a) Cell cycle assays were performed using propidium iodide staining and flow cytometry in the 
indicated cell lines. Cells were treated with 5 nM of romidepsin for the indicated times. In the main graph, the 
fraction of cells in each phase of the cell cycle was calculated as a percentage from the total viable population. 
Subdiploid cells were gated out and not included in this analysis. The data show the means ± s.e.m. of two to 
four independent experiments; significance difference (*p < 0.05) from the control untreated cells. The inset 
show the fraction of cells in the sub-G0/G1 phase, indicative of cell death. (b) Western blot showing p21 and p27 
protein expression in B-cell lymphoma cells treated with 2 or 5 nM romidepsin for the indicated times. Actin 
was used as loading control. Unspecific band is indicated (*). The blots were cropped for improved clarity and 
the full-length blots were included in the Supplementary Information file.
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cell lines upon romidepsin treatment. The gene was upregulated in Raji, DG75 and Ramos cells (Fig. 4c). No sig-
nificant changes were detected in the non-GC Ly03 cell line (Supplementary Fig. S1). B-cells exit from germinal 
centers and plasma cell differentiation program not only requires changes in BCL6 and PRDM1 expression but 
also changes in other regulators such as PAX5 and XBP13. We chose the extensively used cell line model Ramos 
to study the modifications in the expression of these other genes. A clear increase in BLIMP1 protein levels was 
detected in Ramos cells upon romidepsin treatment (Fig. 4d), accompanied by a decrease in PAX5 and XBP1 
mRNA expression (Fig. 4e). Finally, surface markers were analyzed by flow cytometry in Ramos cells. The induc-
tion of plasma cell differentiation was corroborated by the decrease of CD20 (B-cell marker) and the increase of 
CD138 (plasma cell marker) (Fig. 4f).
Altogether these results indicate that romidepsin triggers differentiation towards plasma cell differentiation by 
inhibiting BCL6 expression and this is independent of apoptosis induced by romidepsin.
Figure 4. Romidepsin induces BCL6 downregulation and markers of the plasma cell differentiation program. 
(a) Western blot showing BCL6 protein expression in B-cell lymphoma cells treated with 2 or 5 nM romidepsin 
for the indicated times. Actin was used as loading control. (b) RT-PCR showing CCND2 mRNA expression in 
B-cell lymphoma cells upon romidepsin treatment for the indicated times. mRNA levels were normalized to the 
ribosomal S14 expression. The data show the means ± s.e.m. of at least two independent experiments. (c) RT-PCR 
showing PRDM1 mRNA expression in B-cell lymphoma cells as in (b). (d) Western blot showing BLIMP1 protein 
expression levels in Ramos cells upon romidepsin treatment for the indicated times. (e) RT-PCR showing PAX5 
and XBP1 mRNA expression levels in Ramos cells as in (b). (f) Surface markers CD20 and CD138 analyzed by flow 
cytometry in Ramos cells untreated (black) or treated with 5 nM romidepsin (grey) for 72 h.
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Romidepsin induces BCL6 acetylation. BCL6 regulation is critical for germinal center development. 
Acetylation inactivates BCL6 either under physiological conditions or induced by the histone deacetylase inhib-
itor trichostatin A20. Although we have shown that long-term romidepsin treatment downregulates BCL6, we 
wondered whether romidepsin was able to induce BCL6 acetylation at shorter times. Using Ramos germinal 
center cells as a model, we assayed BCL6 acetylation after romidepsin treatment. Acetylation was assessed by 
immunoprecipitation with an antibody against BCL6, followed by western blot employing an antibody widely 
demonstrated to recognize acetylated lysines in several transcription factors or an antibody against BCL6 
(Fig. 5a). We found increased BCL6 acetylation (3.9-fold) after 3 hours of romidepsin treatment and this acetyla-
tion remains after 6 hours of treatment, although to a lesser extent (2.1-fold) (Fig. 5a top panel). Under all condi-
tions there were approximately equal amounts of BCL6 in each immunoprecipitate (Fig. 5a bottom panel). These 
results are similar to those previously reported using a different HDACi20, demonstrating that romidepsin induces 
BCL6 acetylation.
Romidepsin effects on transcription and histone marks at the BCL6 locus. As previously 
described, BCL6 bound to the BCL6 exon1A represses its own transcription7,36,37. To investigate if the acetylation 
of BCL6 induced by romidepsin had consequences for transcription from the BCL6 locus, we used luciferase 
reporter assay in HEK-293T, a cell line that does not express BCL6 (Fig. 5b). We prepared a luciferase reporter 
construct containing the BCL6 binding site in exon1A, designated as BCL6(exon1A)pGL3. This reporter was 
cotransfected with a BCL6 expression vector (pCDNA-BCL6). Low luciferase activity was detected in cells trans-
fected with pCDNA-BCL6 in the absence of romidepsin due to the BCL6 negative autoregulation. Luciferase 
activity progressively increased with romidepsin in a dose-dependent manner (Fig. 5b). Therefore, the negative 
regulation of BCL6 was counteracted by romidepsin, suggesting that the HDACi is inhibiting BCL6 negative 
autoregulation by acetylation.
We have previously demonstrated that the chromatin regulator CTCF epigenetically regulates BCL6 by 
binding to BCL6 exon1A15. In addition, we have observed that (at timepoints longer than 24 hours) romidepsin 
reduces BCL6 expression (Fig. 4a). Therefore, we aimed to analyze the CTCF occupancy of the BCL6 exon1A 
in that context, using ChIP assays in Ramos cells. Results revealed CTCF binding to the BCL6 exon1A in the 
untreated cells, which strongly diminishes upon treatment with romidepsin (Fig. 5c). Finally, we analyzed the 
effect of romidepsin on the local chromatin structure at exon1A. Ramos cells were treated with romidepsin and 
ChIP assays using antibodies against modified histones were performed. A reduction in the binding of the active 
histone mark H3Ac together with an enrichment of the H3K9me3 repressive histone was observed in the BCL6 
exon1A when cells were treated with romidepsin (Fig. 5d). Together these results indicate that romidepsin pro-
tects the BCL6 regulatory region against CTCF binding thus favoring the incorporation of repressive histone 
marks on BCL6 exon1A.
Collectively our results indicate that, at relatively short time-points, romidepsin inhibition of the BCL6 
deacetylation presumably repress BCL6 function as shown by others20 but increase transcription at the BCL6 
locus. At longer time points, romidepsin modifies the local chromatin structure at the BCL6 locus to suppress 
transcription and consequently BCL6 protein levels, to de-repress transcription of BCL6 target genes.
Romidepsin and JQ1 synergistic effects on proliferation and apoptosis. We next aimed to analyze 
the effect of combined treatment of the epigenetic drugs romidepsin (HDACi) and JQ1 (BRD4i) in Ramos, a 
Burkitt lymphoma cell line. Cell viability analysis (WST-1 method) using different concentrations of both com-
pounds were performed to generate combination index (CI) plot (Supplementary Table S2a). For further exper-
iments, we choose doses close to the IC50 values (5 nM romidepsin and 1 µM JQ1) where synergism (CI < 1) was 
evident (Fig. 6a). Growth curve analysis confirmed the synergistic effect on cell proliferation (Fig. 6b). Annexin V 
staining (Fig. 6c) and cleaved PARP1 (Fig. 6d) were strongly increased after 48 h with the combination treatment, 
together with decreased levels of the antiapoptotic protein BCL-xL, indicating significant synergistic effect of 
romidepsin and JQ1 on apoptotic cell death. Interestingly, the combination treatment dramatically induced the 
expression of γH2AX (Fig. 6d), a well-known marker of DNA damage response.
We also analyzed the effects of romidepsin and JQ1 on the cell cycle. Both compounds alone provoked cell cycle 
arrest and increased the expression of p21 (Fig. 6e). A further increase in p21 levels was detected after 24 h with the 
combination treatment. At longer times, this synergistic effect was not evident presumably due to the high propor-
tion of apoptotic cells (Fig. 6c). The expected decrease in the cyclin A (as a marker of proliferation) and MYC levels 
was also observed (Fig. 6e). Finally, we found downregulation of BCL6 expression that was more pronounced upon 
48 h of combination treatment while BLIMP1 levels were slightly increased with both romidepsin and JQ1 (Fig. 6f).
Similar results were obtained in the less sensitive Raji cells from BL as shown by the CI plot (Fig. 7a, 
Supplementary Table S2b), and to a lesser extent in Toledo and DG75 cells (Supplementary Figs S2 and S3). Clear 
synergistic effects of romidepsin and JQ1 in terms of apoptosis (PARP1 cleavage and γH2AX induction) (Fig. 7b), 
cell cycle arrest (p27 induction, MYC downregulation) and plasmatic differentiation (BCL6 downregulation) 
(Fig. 7c) were observed, indicating that the drugs combination could be effective in aggressive B cells lymphoma.
Discussion
Novel strategies for treatment of aggressive lymphomas are needed. DLBCL, one of the most frequent lympho-
mas in western countries will be refractory to anthracycline conventional treatments in a substantial proportion of 
cases. BCL6 is a key regulator of normal germinal center B-cells and is expressed in Burkitt lymphoma and some 
DLBCL. Transcription factors are attractive targets for therapy because they control programs of gene expression38. 
It is likely that the gene expression program controlled by BCL6 has important roles in driving cell cycle progression 
and proliferation in normal and malignant B-cells35,39 in turn suggesting that BCL6 is an attractive target for these types 
of lymphomas10,12,13. Inhibition of BCL6 has indeed shown very promising results in preclinical studies40. Moreover, 
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Figure 5. Romidepsin effects on BCL6 acetylation, BCL6 autoregulation and local chromatin structure at the 
BCL6 exon1A. (a) Immunoprecipitation showing BCL6 acetylation. Immunoprecipitation of BCL6 protein 
in Ramos cells treated for 3 h and 6 h with 10 nM romidepsin. Total lysates were immunoprecipitated with 
anti-BCL6 antibodies, and the presence of acetylated BCL6 and total amount of BCL6 immunoprecipitated 
was detected by western blot. Densitometry values are shown at the bottom. Inputs are shown as controls. 
Immunoprecipitation of IgG was used as negative control. (b) Romidepsin effect on the negative autoregulation 
of BCL6 gene. Luciferase assay showing the effects of romidepsin on BCL6 exon1A regulatory region. 
HEK-293T cells were co-transfected with either pGL3 vector or with the BCL6 (exon1A)pGL3 reporter 
vector together with the indicated amount of pCDNA-BCL6 expression vector. pRL-null vector was used to 
normalize the transfection efficiency. Transfected cells were exposed to the indicated doses of romidepsin for 
12 h and luciferase activity was determined 48 h after transfection. The data show the means ± s.e.m. of three 
measurements in three independent experiments. a.u., arbitrary units. BCL6 gene regulatory region indicating 
the BCL6 binding site (BCL6BS) is shown. (c) Romidepsin effect on CTCF in vivo binding to BCL6 exon1A. 
ChIP analysis with a mix of three anti-CTCF antibodies, showing the binding of this protein to the exon1A of 
BCL6. Chromatin was prepared from Ramos cells. Relative enrichment was quantified by real-time PCR. The 
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targeting BCL6 might not only be effective on germinal center derived lymphomas but also those ABC-DLBCL cases 
that express it41. However, generation of potent, drug-like inhibitors against BCL6 remains challenging.
We and others, have shown that different epigenetic mechanisms are involved in the modulation of BCL6 
expression in the germinal center reaction14,15. Epigenetic modulators are an attractive and effective strategy in 
a number of malignancies17. Among them, more than ten histone deacetylase inhibitors have shown promising 
results in studies performed in different hematological malignances, including lymphomas18,21,34. HDACi can 
produce a variety of effects including induction of apoptosis, cell cycle arrest, induction of differentiation and 
regulation of immune responses, and these effects are exerted in a cell type specific manner21,22,34,42. Some of these 
effects are generated by the inhibition of activity of HDACs while others might be the consequence of modifica-
tion of other cellular proteins by acetylation. In this study a number of BL derived cell lines were used to evaluate 
the effect of romidepsin, a potent HDACi that has been approved for treatment of different types of T cell lym-
phomas but its role on B cell lymphomas is yet not well known. BL shows high level BCL6 expression and BL cell 
lines have been used to elucidate many aspects of BCL6 action35. We also analyzed the effect of romidepsin in two 
GC-DLBCL and ABC-DLBCL cell lines, for comparison.
Romidepsin induced apoptosis in metabolically sensitive lymphoma B-cell lines. Several reports have shown a 
role for the mitochondrial apoptotic pathway in HDACi mediated apoptosis21,42. In some cases BCL2 or BCL-xL, 
which block the intrinsic apoptotic pathway, are able to overcome the effects of a number of HDACi. Therefore, a 
differential expression of the pro-apoptotic and the anti-apoptotic BCL2 family members might explain the vary-
ing response to romidepsin. In healthy B-cells, BCL2 expression is reduced when B-cells enter the germinal center 
reaction43. Although the basal expression of BCL2 was variable among the cells used in this study, no relationship 
between BCL2 expression and sensitiveness to romidepsin was observed. This is not surprisingly since romidep-
sin has been shown to induce apoptosis even in models overexpressing BCL2, but not in BCL-xL models33. 
Although down-regulation of BCL-xL does not imply an immediate death43, the reduction in the anti-apoptotic 
BCL-xL in Ramos and Toledo cells compared to the unchanged levels observed in the DG75 insensitive cell line, 
imply that BCL-xL might be a good marker for monitoring romidepsin effect in germinal center cells. This is in 
agreement with previous studies showing how expression of BCL-xL might confer a drug resistance phenotype44. 
Interestingly, BIM was upregulated in both DLBCL (Toledo and Ly03) cells in the presence of romidepsin, which 
might explain the apoptosis observed in those cell lines, given that BIM plays a critical role in HDACi induced 
apoptosis45,46. In DG75 and Ramos cells, BIM levels are maintained while MCL1 protein transiently increases 
upon romidepsin treatment. Since MCL1 is essential for the survival of plasma cells47, this transient expression of 
MCL1 detected in response to romidepsin might be providing a short-term window to allow cells to differentiate 
into plasma cells and/or die by apoptosis.
It is known that GC B-cells stop proliferating in order to be able to differentiate into plasma cells. Accordingly, 
cell cycle arrest in G0/G1 phase was observed, together with the increase in p21 and p27, in most of the lymphoma 
cells analyzed upon exposure to romidepsin. This is in line with previous reports showing, that accumulation of 
cycling dependent kinase inhibitors is a general effect shared by most of all the histone deacetylase inhibitors, 
when used on various malignancies19,34.
In this study we have shown that romidepsin (i) induces BCL6 acetylation, which inhibits BCL6 negative 
autoregulation, and (ii) protects the BCL6 regulatory region against CTCF binding thus favouring the incorpo-
ration of repressive histone marks. In agreement, treatment of DLBCLs with other HDACi has been shown to 
induce hyperacetylation of BCL6, reactivation of repressed target genes and induction of apoptosis20,48. In our 
study, the romidepsin-mediated downregulation of BCL6 was also associated with plasma cell differentiation, as 
shown by induction of PRDM1 (BLIMP1) levels and the expression of plasma cell surface marker (CD138). In 
treated Ramos cells, PAX5 mRNA levels were downregulated, PAX5 being necessary for B-cells to maintain their 
germinal center identity49,50. However, when we analyzed the expression of XBP1, a gene that acts downstream 
of PRDM1-BLIMP1, we found no upregulation, suggesting that romidepsin might be triggering a partial plasma 
cell differentiation program but is not sufficient for terminal plasma cell differentiation. Therefore, as expected the 
mature plasma cell phenotype was not completely reached because cell lines have limited differentiation capacity. 
The effects of romidepsin on lymphoma B cells are summarized in Fig. 8.
Combination of HDACi with drugs targeting different cellular pathways are being used with promising results 
in a number of tumors including lymphomas18,19. Recently, combination treatments of HDAC and BET inhib-
itors have been described to have synergistic effects in different cancers51–61. In order to further improve the 
response of aggressive lymphoma cells, we explored the effects of romidepsin together with the BRD4 inhibitor 
JQ1. BRD4i inhibits MYC expression, frequently deregulated in hematopoietic malignancies28,62. Strong synergis-
tic effect of romidepsin and JQ1 activating DNA-damage response and apoptotic cell death was found in Ramos 
cells (from BL) as assessed by γH2AX induction, annexin V binding and PARP1 cleavage. Notably, synergy in 
apoptosis and plasma cell differentiation was also found in the less sensitive Raji and DG75 (from BL) and Toledo 
(from GC-DLBCL) cells. In agreement with our results, two recent reports demonstrated synergistic effects of 
romidepsin and JQ1 in solid tumors55,56. This novel combination therapy can be useful to treat poor prognosis or 
non-responders low survival lymphoma patients.
fold enrichment was determined as indicated in Methods section. (d) Presence of histone marks at the BCL6 
exon1A upon treatment with romidepsin. ChIP analysis with CTCF, H3Ac and H3K9me3 antibodies, showing 
the presence of these proteins at the exon1A of BCL6. Chromatin was prepared from Ramos cells treated 
with romidepsin. Relative enrichment was quantified by real-time PCR. The fold enrichment of a particular 
target sequence was determined as indicated in Methods section. Bottom panel shows typical PCR products 
after the ChIP assays. The gels were cropped for improved clarity and the full-length gels were included in the 
Supplementary Information file.
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In conclusion, our findings provide new insights into the molecular mechanisms of romidepsin effect on 
aggressive lymphomas: cell cycle arrest and induction of plasma differentiation is induced upon exposure to the 
drug and this effect appear to be related to the inhibition of BCL6 expression and function. Romidepsin also 
induces a variable apoptotic effect that is significantly increased upon treatment with the BET inhibitor JQ1, 
which reduces MYC function. Overall our data show a potential role for romidepsin and JQ1 combination for the 
treatment of aggressive and BCL6 expressing lymphomas.
Figure 6. Synergistic effects of romidepsin and JQ1 in Ramos B-cell lymphoma cells. (a) Combination index 
plot showing synergistic effect (arrow) of romidepsin (5 nM) plus JQ1 (1 µM) on the proliferation of Ramos 
cells. (b) Growth curves of Ramos cells untreated (Control) or treated with romidepsin and/or JQ1 for up to 
72 h. (c) Annexin V staining to assess apoptosis in Ramos cells untreated (Control) or treated with romidepsin 
and/or JQ1 for 48 h. Results shown are the means ± s.e.m. of three experiments; significance difference 
(*p < 0.03; ***p < 0.001) from the control untreated cells. (d) Western blot showing cleaved PARP1 and 
BCL-xL and γH2AX protein levels in Ramos cells treated with romidepsin and/or JQ1 for the indicated times. 
Actin was used as loading control. Densitometry values are shown at the bottom, normalized to the control. (e) 
Western blot showing p21, MYC and cyclin A protein levels in Ramos cells treated as above. (f) Western blot 
showing BCL6 and BLIMP1 protein levels in Ramos cells treated as above. The blots were cropped for improved 
clarity and the full-length blots were included in the Supplementary Information file.
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Methods
Cell lines culture and drugs treatment. Raji, DG75, Ramos, Toledo and Ly03 B-cell lymphoma cell lines 
(origin and features in Supplementary Table S1) were grown in RPMI-1640 supplemented with 10% or 20% fetal 
calf serum (Lonza) under standard conditions15 and confirmed to be mycoplasma free. BCL6, MYC and BCL2 loci 
Figure 7. Synergistic effects of romidepsin and JQ1 in Raji B-cell lymphoma cells. (a) Combination index plot 
showing synergistic effect (arrow) of romidepsin (5 nM) plus JQ1 (1 µM) on the proliferation of Raji cells. (b) Western 
blot showing cleaved PARP1 and BCL-xL and γH2AX protein levels in Raji cells treated with romidepsin and/or JQ1 
for the indicated times. Actin was used as loading control. Densitometry values are shown at the bottom, normalized 
to the control. (c) Western blot showing p27, MYC and BCL6 protein levels in Raji cells treated as above. The blots 
were cropped for improved clarity and the full-length blots were included in the Supplementary Information file.
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status in the studied cell lines were determined by FISH analysis (Supplementary Table S1).
Romidepsin was kindly provided by Celgene (Summit, NJ, USA). (+)-JQ1 was purchase from Cayman 
Chemical (Ann Arbor, MI, USA). Drugs were diluted in DMSO and stored at −20 °C. To study the effects of the 
drugs, exponentially growing cells were treated with the different drug concentrations for several time points, 
depending on the experiment and cell line.
Cell proliferation and viability assays. Cells were treated with different doses of romidepsin and/or 
JQ1 for up to 96 h. Cell proliferation and cell viability was measured using the Guava ViaCount reagent (Merck 
Millipore, Darmstadt, Germany) or the NucleoCounter system (Chemometec, Allerod, Denmark). Metabolic 
activity of cells was measured using the WST-1 method (Roche, Basilea, Switzerland) which allows the quantifi-
cation of the number of viable cells by the cleavage of tetrazolium salt WST-1 to formazan dye. Romidepsin and 
JQ1 combination effects were determined using the combination index (CI) values, analyzed by the Chou-Talalay 
method using CompuSyn Software63.
Cell cycle, apoptosis and differentiation analysis. Cell cycle analysis were performed using propid-
ium iodide staining as previously described64. Cells were fixed with cold ethanol and resuspended in PBS-citrate 
Na-BSA containing RNase and propidium iodide. The stained cells were analyzed by flow cytometry (FACSDiva 
cytometer). Annexin V-PE Apoptosis detection Kit (Immunostep, Salamanca, Spain) was used for the detection 
of early apoptotic cells. Cells were treated with romidepsin and JQ1 for 24 and 48 h and Annexin V-binding was 
analyzed by flow cytometry (FACSDivaTM software, BD biosciences, NJ, USA). The cleavage of poly(ADP-ribose)
polymerase-1 (PARP1), indicative of apoptosis, was analyze by immunoblot.
Cell surface markers were analyzed in the Hematology Department of Hospital Marqués de Valdecilla to 
assess cells differentiation. After 72 h of culture in the presence of 5 nM romidepsin, cell surface markers were 
analyzed by flow cytometry using the BD FACSDiva flow-cytometer following standard procedures65. The con-
jugated antibodies used were: anti-CD20 PE (BD 345793) from BD Biosciences and anti-CD138 FITC (Rafer; 
Zaragoza, Spain, IQP 153 F).
RNA analysis by Reverse transcription (RT) and polymerase chain reaction (PCR). Total RNA 
was isolated by using the Trizol reagent (Invitrogen, Carlsbad, CA, USA). For reverse transcription, first-strand 
cDNA was synthesized from 1 µg of total RNA using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, 
USA). Quantitative PCR was performed with a IQTM SyBR Green Supermix kit (Bio-Rad). mRNA expression 
was normalized to ribosomal protein S14 mRNA levels (primers shown in Supplementary Table S3). Results 
were analyzed by comparative ΔΔCt method and expressed as mean ± SEM of duplicate PCRs from at least two 
independent experiments.
Figure 8. Proposed model for epigenetic drugs effect on B-cell lymphoma cells and BCL6 regulation. 
Romidepsin induces cell cycle arrest accompanied with increased levels of p27 and p21 in most lymphoma cells. 
The sensitive lymphoma B-cells undergo apoptosis as shown by cleavage of PARP1 and positive Annexin V 
staining. Downregulation of BCL6 and PAX5 together with increase on PRDM1 (BLIMP1) is also observed, and 
plasma cell differentiation program is initiated. Synergistic effect of romidepsin and JQ1 mainly in apoptosis 
induction (thicker line) is demonstrated. In B-cell lymphoma cells, CTCF is bound to BCL6 exon1A impairing 
BCL6 binding to its negative autoregulation site and is associated with marks representative of an open 
chromatin state (H3Ac). In the presence of romidepsin BCL6 is acetylated, CTCF is not longer bound to BCL6 
exon1A and repressive histone marks (H3K9me3) are incorporated. The consequent downregulation of BCL6 
correlates with plasmatic differentiation as shown above.
13Scientific RepoRtS |         (2019) 9:16495  | https://doi.org/10.1038/s41598-019-52714-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
Immunoblot and immunoprecipitation assays. Cells were lysed in lysis buffer (1% NP-40, 100 mM 
NaCl, 20 mM Tris-HCl pH 7.4, 10 mM NaF, 1 mM orthovanadate and protease and phosphatase inhibitors 
cocktail). Samples were sonicated and subjected to SDS-PAGE and immunoblot as described previously66. 
The antibodies used were: anti-actin (I-19, sc1616), anti-BCL6 (N-3, sc858), anti-PARP1 (H-250, sc7150), 
anti-CycA (H-432, sc751) from Santa Cruz Biotech. (Santa Cruz, CA, USA); anti-BCL-xL (ab7974) from 
Abcam (Cambrigde, UK); anti-BCL2 (2876), anti-BIM (C34C5), anti-MCL1 (4572), anti-BLIMP1 (C14A4), 
anti-GAPDH (14C10), anti-cMYC (9402S), anti-p27 (3686), anti-p21 (2947) from Cell Signalling Tech. (Danvers, 
MA, USA); Anti-phospho-Histone H2A.X (Ser139) (05–636) from Millipore (Darmstadt, Germany). Blots were 
developed with secondary antibodies conjugated to IRDye680 or IRDye800 (Li-Cor Biosciences, LiCor, Lincoln, 
NE, USA) and immunocomplexes were detected with an Odyssey infrared-imaging system (Li-Cor Biosciences). 
Some blots were revealed with the ECL system (Bio-Rad).
Immunoprecipitations were performed essentially as described67. For detection of the endogenous acetylated 
BCL6, Ramos cells were lysed in lysis buffer (50 mM Tris-HCl, 250 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholic 
acid, 0.1% SDS) containing 1 μM romidepsin and protease inhibitors cocktail. Protein extracts were immunopre-
cipitated with 3 μg of a mouse monoclonal antibody against BCL6 (PG-B6P) or unspecific immunoglobulins used 
as a control (IgGs sc-2025), from Santa Cruz Biotech. Dynabeads-protein G-bound magnetic beads (Invitrogen) 
were used to capture protein-antibody immunocomplexes. Immunocomplexes were resolved by SDS-PAGE and 
analyzed by western blot with antibody against acetyl lysine (9441, Cell Signaling). The same filter was then incu-
bated with an anti-BCL6 (N3, sc858) rabbit polyclonal antibody.
Luciferase reporter assays. HEK-293T cells were transiently transfected using polyethilenimine (PEI) 
transfection reagent (Polysciences Inc., Warrington, PA, USA) as previously described15 and reporter experi-
ments were performed essentially as described20. 0.3 µg of the pGL3-basic vector (Promega) or 0.35 µg of the 
BCL6(exon1)-pGL3 reporter vector68 and 0.1 µg of the pRL-null vector (Promega) were cotransfected with 
pCDNA-BCL6 expression vector15. Cells were treated for 12 hours with different concentrations of romidepsin. 
Luciferase activities were measured 48 hours after transfection using the Dual-Glo Luciferase Reporter System 
(Promega, Madison, WI, USA) in a Luminometer TD 20/20 Turner Designs. For each determination, luciferase 
activity was calculated as the Firefly activity normalized by the Renilla activity. Luciferase activity in arbitrary 
units (a.u.) was shown as the increase in activation relative to the activity of the pGL3 vector alone and the maxi-
mum value for each condition was set to 100.
Chromatin immunoprecipitation (ChIP). For ChIP experiments chromatin was prepared from Ramos 
cells treated with 5 mM romidepsin for 48 h. ChIP assays were performed using the Pierce Magnetic ChIP Kit 
(Thermo Fisher Scientific, Waltham, MA, USA) following the manufacturer’s protocol. Cells were fixed in for-
maldehyde, lysed, treated with Micrococcal nuclease and sonicated using a Bioruptor UCD-200TM (Diagenode, 
Liège, Belgium). ChIP was performed using ChIP-Grade Protein A/G Magnetic Beads coupled to different anti-
bodies: anti-CTCF-Ab-1 (07-729) from Millipore, anti-CTCF (ab10571) from Abcam; anti-CTCF (612149) from 
BD and anti-H3acetylated (06-599) from Millipore; anti-H3K9me3 (ab8898) from Abcam. Real-time PCR of 
immunoprecipitated DNA was performed in duplicate with equal amounts of specific antibody immunopre-
cipitated sample, control (beads) and input. Primers used for ChIP assays corresponding to the BCL6 exon 1A 
(+257) were: 5′-GCACTCCCCCTCTTATGTCA-3′ and 5′-GATTTGGAGGTTCCGGTTC-3′15. The compara-
tive cycle threshold approach was used for the data analysis15. The signals were normalized to the inputs and the 
fold enrichment was calculated relative to the control sample (no-antibody). The values are the mean ± S.E.M. of 
two to six independent experiments. Normalization of histone marks was based on the ChIP-IT qPCR analysis 
kit (Active motif North America, Carlsbad, CA, USA).
Statistical analysis. Results were presented as the mean of two to four determinations with error bars repre-
senting the standard error of the mean. The significance of differences was determined by the unpaired Student’s 
t test; a p < 0.05 was considered to be statistically significant.
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